▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / TKPHF

TKPHF — TAKEDA PHARMACEUTICAL CO LTD

—
NYSE · Health Care · Pharmaceuticals · CIK 1395064 ·
Last close
$31.19
Market Cap
$49.80B
52W High
$35.75
52W Low
$29.33
ADV30
14,487
Next earnings
2026-07-30
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,094,541,000,000 688,837,000,000 42,068,000,000 -368,471,000,000 15,511,506,000,000 595,054,000,000 8,080,857,000,000
Dec 2025 1,191,698,000,000 790,550,000,000 168,822,000,000 103,640,000,000 15,408,774,000,000 654,937,000,000 7,764,684,000,000
Sep 2025 1,112,796,000,000 732,735,000,000 68,996,000,000 -11,802,000,000 14,470,300,000,000 681,486,000,000 7,338,611,000,000
Jun 2025 1,106,685,000,000 722,010,000,000 184,565,000,000 124,243,000,000 14,004,537,000,000 350,008,000,000 7,138,357,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,189,062,000,000
Investing CF
$-330,806,000,000
Financing CF
$-721,117,000,000
CapEx
$-442,990,000,000
Dividends Paid
$-312,852,000,000
Buybacks
$-101,581,000,000
EPS Diluted TTM
$78.23
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$1,095,662,000,000
Inventory
$1,407,192,000,000
Receivables
$757,921,000,000
ST Investments
$107,004,000,000
EBIT TTM
$496,862,000,000
Pretax Income TTM
$205,369,000,000
Interest Exp TTM
$291,493,000,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,505,720,061,952
EBITDA
$1,236,273,987,584
Free Cash Flow
$672,782,745,600
Enterprise Value
$4,931,786,899,456
Total Cash
$595,053,969,408
Total Debt
$5,476,358,029,312
Shares Out
1,596,751,439
Trailing EPS
$-0.59
Book Value
$28.94
ROE
-2.1%
ROA
2.6%
Div Yield
4.16%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2026 4,505,720,000,000 464,451,000,000 -152,390,000,000 15,511,506,000,000 8,080,857,000,000 — 1,041,431,000,000
Mar 2025 4,581,551,000,000 466,370,000,000 107,928,000,000 14,248,344,000,000 7,312,365,000,000 — 1,057,182,000,000
Mar 2024 4,263,762,000,000 309,901,000,000 144,067,000,000 15,108,792,000,000 7,834,787,000,000 — 716,344,000,000
Mar 2023 4,027,478,000,000 587,812,000,000 317,017,000,000 13,957,750,000,000 7,603,079,000,000 — 977,156,000,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.81

Peers — same industry

TickerNameMarket CapLastDaily %
TAK TAKEDA PHARMACEUTICAL CO LTD $55.06B $17.24 —
REGN REGENERON PHARMACEUTICALS, INC. $67.58B $656.01 —
ALNY ALNYLAM PHARMACEUTICALS, INC. $36.28B $271.77 —
TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD $35.88B $30.81 —
TEVJF TEVA PHARMACEUTICAL INDUSTRIES LTD $33.07B $28.40 —

News headlines (Yahoo Finance, 1h cache)

Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
2026-07-24 14:40 · Yahoo
Change in Siegfried's Management Team
2026-07-16 22:32 · Yahoo
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
2026-07-16 22:00 · Yahoo
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
2026-07-15 17:02 · Yahoo
Takeda and Indonesia partner on plasma-derived therapies
2026-07-13 10:13 · Yahoo
Moderna, Takeda and Capricor on the verge of notching big drug approvals
2026-07-13 08:20 · Yahoo
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
2026-07-12 23:00 · Yahoo
Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?
2026-07-09 17:29 · Yahoo
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
2026-07-08 18:05 · Yahoo
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
2026-07-07 15:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →